罗莫佐单抗在慢性肾脏病合并骨质疏松患者中的疗效与安全性:一篇叙述性综述
本文为叙述性综述,探讨骨质疏松对慢性肾脏病(CKD)患者的影响,详述其发病机制尤其是无力型骨病的作用,并阐述Wnt通路对骨转换和血管钙化的影响,最后深入概述罗莫佐单抗治疗CKD合并骨质疏松患者的有效性及已报告的安全性。
要点
- CKD是骨质疏松的独立危险因素,CKD患者骨丢失管理包括非药物和药物策略。
- 近期研究显示多数早期CKD患者骨转换偏低,罗莫佐单抗抑制骨吸收和促进骨形成的双重机制可能对此类患者有帮助。
- 对血管钙化增加的担忧仍需阐明。
核心结论
- 罗莫佐单抗抑制骨吸收和促进骨形成的双重机制可能对早期CKD骨转换偏低的患者有帮助,但对血管钙化增加的担忧仍需阐明。
研究设计与样本
- 本文为叙述性综述,探讨骨质疏松对CKD患者的影响、发病机制、Wnt通路及罗莫佐单抗的有效性与安全性。
主要发现
- CKD是骨质疏松的独立危险因素。
- 近期研究显示多数早期CKD患者骨转换偏低。
- 罗莫佐单抗靶向硬骨抑素,抑制骨吸收并促进骨形成。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) is an independent risk factor for osteoporosis. Managing bone loss in CKD patients involves both non-pharmacological and pharmacological strategies. Romosozumab, a monoclonal antibody that targets sclerostin, represents a major advancement in osteoporosis treatment. Recent studies showed that the majority of patients with early stages of CKD tend to have low bone turnover. The dual romosozumab mechanism of suppressing bone resorption and augmenting bone formation could be helpful in those patients. However, the concerns about increasing vascular calcification need to be clarified. This review explores the effects of osteoporosis on CKD patients, detailing its pathogenesis especially the role of adynamic bone disease, shedding light on Wnt pathways and their influence on bone turnover and vascular calcifications. Lastly, we provide an in-depth overview of romosozumab and its effectiveness and reported safety in treating patients with CKD and osteoporosis.
引用
- Abdalbary M, Amin AM, Elaraby A, et al. Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review. Osteoporos Int. 2025. PMID: 41171457. doi:10.1007/s00198-025-07707-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。